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doi:10.1016/j.ejvs.2008.09.008Abstract Objectives: To assess long-term outcome of patients at high cardiac risk undergoing
endovascular or open AAA repair.
Methods: Patients undergoing open or endovascular infrarenal AAA repair with 3 cardiac risk
factors and preoperative cardiac stress testing (DSE) at 2 university hospitals were studied.
Main outcome was cardiac event free and overall survival. Multivariate Cox regression analysis
was used to evaluate the influence of type of AAA repair on long-term outcome.
Results: In 124 patients (55 endovascular, 69 open) the number and type of cardiac risk
factors, medication use and DSE results were similar in both groups. In multivariable analysis,
adjusting for cardiac risk factors, stress test results, medication use, and propensity score en-
dovascular repair was associated with improved cardiac event free survival (HR 0.54; 95% CI
0.30e0.98) but not with an overall survival benefit (HR 0.73; 95% CI 0.37e1.46). Importantly,
statin therapy was associated with both improved overall survival (HR 0.42; 95% CI 0.21e0.83)
and cardiac event free survival (HR 0.45; 95% CI 0.23e0.86).
Conclusions: The perioperative cardiac benefit of endovascular AAA repair in high cardiac risk
patients is sustained during long-term follow-up provided patients are on optimal medical
therapy but it is not associated with improved overall long-term survival.
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Patient undergoing abdominal aortic aneurysm repair are at
significant risk for both perioperative and long-term
cardiovascular events. In particular patients at high cardiac
risk might benefit from endovascular AAA repair. However,
no randomized trials comparing open and endovascular
treatment have been reported on patients at high cardiac
risk. For example, less than half of the patients in the
DREAM trial (44%) and EVAR-1 trial (43%) had a history of
cardiac disease.1,2 A major limitation of non-randomized
comparative studies between open and endovascular
surgical procedures conducted so far is the lack of objec-
tive criteria for baseline cardiac condition.3
Preoperative cardiac stress testing such as dobutamine
stress echocardiography (DSE) provides an objective
assessment of the presence and extent of coronary artery
disease.4 In a previous study we used this modality to
compare perioperative outcome after open or endovascular
AAA repair and found that endovascular repair was superior
in terms of cardiovascular outcome.5 The long-term
outcome of these high-risk patients however remained
ill-defined.
Therefore we expanded the study population of the
previous study and conducted long-term follow-up of these
patients. The aim of the present study was to evaluate the
long-term effect of endovascular AAA repair compared to
open AAA repair in patients at clinical high cardiac risk on
cardiac complications and mortality.
Methods
Patients
The study population was composed of patients with 3 or
more cardiac risk factors who underwent elective abdom-
inal aneurysm repair between January 2000 and January
2006 at two tertiary referral centers, Erasmus University
Medical Center Rotterdam, the Netherlands and University
Medical Center Utrecht, the Netherlands and had a preop-
erative cardiac stress test. The choice for either repair
method was at the discretion of the treating vascular
surgeon and was mainly based on anatomical consider-
ations. The study was approved by the Erasmus MC medical
ethics committee.
Preoperative cardiac risk assessment
All patients were routinely screened for cardiac risk
factors, including age over 70 years, history of or presence
of angina pectoris, previous myocardial infarction, heart
failure, stroke, renal failure (serum creatinine
>170 mmol/l), and diabetes mellitus. The presence of
hypertension and chronic obstructive pulmonary disease
(COPD) was noted as well. A patient was classified as
having COPD at the preoperative screening visit according
to symptoms and pulmonary function test (i.e. FEV1< 70%
of maximal age and gender predictive value). According to
the ACC/AHA guidelines all patients with 3 or more
cardiac risk factors underwent cardiac stress testing prior
to surgery.Perioperative medication use was noted including ACE-
inhibitors, platelet aggregation inhibitors, beta-blockers,
calcium antagonists, coumarin derivatives, diuretics,
nitrates, and statins. Patients unable to take medication
orally perioperatively were switched to intravenous
formula. If no intravenous formula was available, i.e. sta-
tins and ACE-inhibitors, oral medication was restarted as
soon as possible after surgery.
Cardiac stress testing
Resting echocardiography was used to estimate the left
ventricular ejection fraction using the Simpson rule.
Cardiac stress testing was performed by dobutamine
echocardiography as previously described.6 Myocardial
stress induced ischemia was assessed using a semi-quanti-
tative evaluation; a 5-point score in a 17-segement model.
Limited ischemia was defined by the presence of 1e4
ischemic segments, while extensive ischemia was defined
by 5 ischemic segments.
Outcome
All patients were monitored for cardiac events after
abdominal aortic aneurysm repair. Twelve-lead ECG and
serum troponin-T levels were systematically determined on
days 1, 3, and 7 postoperatively or at discharge. The
primary outcome of the study was the incidence of all-
cause mortality and the combination of myocardial infarc-
tion and all-cause death during long-term follow-up.
Myocardial infarction was defined as the presence of 2 out
of the following 3 criteria: (1) Characteristic ischemic
symptoms lasting > 20 min, (2) electrocardiographic
changes including acute ST elevation followed by appear-
ance of Q waves or loss of R waves, or new left bundle
branch block, or new persistent T wave inversion for at
least 24 h, or new ST segment depression which persists
>24 h, and (3) a positive troponin T, i.e. >0.10 ng/ml, or
peak CK-MB >8% of an elevated total creatinine phospho-
kinase with characteristic rise and fall.7 Survival status was
confirmed by contacting the civil service registry.
Statistical analysis
Continuous data are presented as median values and cor-
responding 25th and 75th percentiles, whereas dichoto-
mous data are presented as percentages. Differences in
clinical characteristics between patients undergoing endo-
vascular repair or open repair were evaluated by Wilcoxon’s
nonparametric tests, Chi-square tests or Fisher’s exact
tests, as appropriate. The incidence of events over time
was further examined by the KaplaneMeier method,
whereas a log-rank test was applied to evaluate differences
between the two treatment modalities. We developed
a propensity score for the likelihood of undergoing either
open or endovascular AAA repair and used applied multi-
variate logistic regression analysis to calculate the
propensity score. The association of type of AAA repair,
cardiovascular risk factors and medication use with long-
term events was assessed via multivariate Cox regression
analysis, including the propensity score, with stepwise
648 O. Schouten et al.backward removal. The limit of statistical significance was
set at PZ 0.05 (two sided). All analysis was performed
using the statistical software SPSS for Windows 12.0.1 (SPSS
Inc., Chicago, Illinois, USA).
Results
Patient characteristics
A total of 124 patients with 3 or more clinical cardiac
risk factors were included in this study. Of these, 69
patients underwent open AAA repair and 55 patients
underwent endovascular AAA repair. Clinical baseline
characteristics of these patients are shown in Table 1.
Almost all (92%) patients were male, their mean age was
74 6 years, and the median AAA diameter was 60 mm
(interquartile range 55e70 mm). There were no statis-
tically significant differences between patients under-
going open or endovascular AAA repair in terms of
clinical characteristics or medication use. During non-
invasive stress testing approximately half (47%) of all
patients had stress inducible myocardial ischemia. A
total of 46 (37%) patients had mild myocardial ischemia
while another 12 (10%) patients had extensive myocar-
dial ischemia. There was no difference in, mild or
extensive myocardial ischemia between the open and
endovascular group (respectively 54% vs 53%, 35% vs 40%
and 12% vs 7%).Table 1 Baseline clinical characteristics of patients undergoing
All patients (NZ 124)
Men 114 (92%)
Age (mean, SD) 74 6
Heart rate prior to surgery 65 12
Risk factors
Previous angina pectoris 77 (62%)
Previous myocardial infarction 107 (86%)
Previous heart failure 25 (20%)
Previous CABG or PTCA 60 (48%)
CVA or TIA 46 (37%)
Diabetes mellitus 18 (14%)
Renal failure 28 (22%)
Systemic hypertension 52 (42%)
COPD 48 (38%)
Stress echocardiography
No ischemia 66 (53%)
Limited ischemia 46 (37%)
Extensive ischemia 12 (10%)
Medication at screening
Platelet aggregation inhibitors 90 (72%)
ACE-inhibitors 51 (41%)
Diuretics 42 (34%)
Nitrates 35 (28%)
Beta-blockers 108 (86%)
Statins 78 (63%)
Calcium-antagonists 42 (34%)Perioperative outcome
Overall 30-day mortality was 4.3% for the open group and
0% for the endovascular group. An additional 3 (4.3%)
patients in the open group died during hospitalization but
after 30 days of the index procedure. The combined 30-day
endpoint of non-fatal myocardial infarction and all-cause
death was 12 (17%) in the open and 2 (4%) in the endovas-
cular group (pZ 0.02). The length of hospital stay was
significantly shorter in patients with endovascular AAA
repair (median 3 vs 11 days, p< 0.001).
Long-term outcome
Type of repair
During a median follow-up of 3.3 years (interquartile range
1.8e5.6 years) a total of 39 (31%) patients died and a total
of 55 (45%) patients reached the combined endpoint of all-
cause death and MI. As is shown in Fig. 1a, during long-term
follow-up there was no significant difference in overall
survival between endovascular and open AAA repair
(pZ 0.38). Also in multivariate analysis patients treated
with endovascular had no significant better survival rate
(HR 0.73, 95% CI 0.37e1.46, Table 2). However, patients
who underwent endovascular AAA repair did have a statis-
tically significant better cardiac event free survival as
compared to patients treated with open repair (Fig. 1b, HR
0.54, 95% CI 0.30e0.98, Table 3). It should be notedopen and endovascular abdominal aneurysm repair
Open (NZ 69) Endovascular (NZ 55) P
64 (93%) 50 (91%) 0.75
74 6 74 7 0.66
66 13 64 9 0.23
41 (59%) 36 (64%) 0.71
60 (87%) 47 (84%) 0.80
12 (17%) 13 (23%) 0.50
33 (48%) 27 (48%) 0.99
29 (42%) 17 (30%) 0.20
10 (15%) 8 (14%) 0.95
14 (20%) 14 (25%) 0.67
32 (46%) 20 (36%) 0.28
28 (41%) 20 (36%) 0.57
37 (54%) 29 (53%) 0.66
24 (35%) 22 (40%)
8 (12%) 4 (7%)
40 (73%) 40 (71%) 0.84
32 (47%) 19 (34%) 0.15
25 (59%) 17 (41%) 0.57
19 (27%) 16 (29%) 0.95
60 (87%) 48 (86%) 0.88
41 (59%) 37 (67%) 0.46
24 (35%) 18 (32%) 0.85
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Figure 1 (a) Overall survival of patients undergoing endovascular or open AAA repair. Open AAA repair. Endovascular AAA
repair.(b). Cardiac event free survival of patients undergoing endovascular or open AAA repair. Open AAA repair Endovascular
AAA repair.
Cardiac High-Risk and EVAR 649however that this benefit was mainly driven by the 30-day
events. If the first 30 days after surgery are not taken into
account there would have been a similar cardiac event free
survival among patients treated by endovascular or open
repair (HR 0.89, 95% CI 0.44e1.77, pZ 0.73).
Medical therapy
While type of AAA repair did not have a significant impact
on overall long-term survival aggressive medical therapy
did seem to be associated with improved overall survival.
Patients on statin therapy had a significant survival benefit
over patients not on statin therapy; 5-year overall survival
77% vs 53% respectively (HR 0.42, 95% CI 0.21e0.83, Table 2).
Also cardiac survival event free was significantly better in
patients on statin therapy (HR 0.45, 95% CI 0.23e0.86,
Table 3). As is shown in Fig. 2a, b the perioperative benefit
of endovascular repair was only sustained in patients on
statin therapy in contrast to patients not on statin therapy
(Fig. 3). The prescription rate of statins gradually increased
over the studied years, from 38% in 2001/2002 to 67% in
2003/2004 and 88% in 2005/2006 (p< 0.001). The vast
majority of patients were on beta-blocker therapy. Impor-
tantly the mean heart rate prior to surgery was 65 beats per
minute, indicating adequate beta-blocker dosing in most
patients. However, 35 (28%) patients had inadequate heart
rate control with a rate of >70 beats per minute. PatientsTable 2 Significant predictors of long-term overall
survival status when clinical characteristics, propensity
score for type of surgery, medication use and year of
surgery were entered as independent variables into a Cox
regression model with stepwise backward removal
HR 95% CI P-value
Endovascular treatment 0.73 0.37e1.46 0.37
Age (per year increase) 1.10 1.03e1.17 0.003
Stress inducible
myocardial ischemia
1.95 1.03e3.89 0.04
Statin use 0.42 0.21e0.83 0.01
Heart rate <70 bpm 0.26 0.13e0.54 <0.001
Platelet aggregation inhibitor 0.47 0.23e0.97 0.04on adequate beta-blocker therapy had a significantly better
overall survival (HR 0.26, 95% CI 0.13e0.54, Table 2) and
cardiac event free survival (HR 0.53, 95% CI 0.29-0.97,
Table 3). Importantly, there was no significant interaction
between statin use and adequate beta-blocker dosing.
Furthermore, as shown in Table 2 patients who were on
platelet aggregation inhibitors had a better overall survival
than did patients who were not on antiplatelet therapy (HR
0.47; 95% CI 0.23e0.97, pZ 0.04).
Discussion
This study showed that, despite a reduced incidence of
adverse perioperative events, endovascular repair of
elective infrarenal AAA in cardiac high-risk patients has
a similar long-term survival, compared to patients under-
going open AAA repair. However, the perioperative cardiac
benefit is sustained during a median follow-up of 3.3 years
in this high-risk population provided patients are on
optimal medical therapy. Furthermore, aggressive medical
treatment seems to have more impact on overall and
cardiac event free survival than does the choice of AAA
treatment modality.
Patients undergoing major noncardiac surgery are at
significant risk of cardiovascular morbidity and mortality.
The prognosis after vascular surgery is predominantlyTable 3 Significant predictors of long-term cardiac event
free survival status when clinical characteristics, propensity
score for type of surgery, medication use and year of
surgery were entered as independent variables into a Cox
regression model with stepwise backward removal
HR 95% CI P-value
Endovascular treatment 0.54 0.30e0.98 0.04
Age (per year increase) 1.05 1.01e1.10 0.03
Stress inducible
myocardial ischemia
2.60 1.45e4.67 0.001
Statin use 0.45 0.23e0.86 0.02
Heart rate <70 bpm 0.53 0.29e0.97 0.04
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Figure 2 (a) Overall survival of patients undergoing endovascular or open AAA repair, divided into statin users or non-users.
Statin users undergoing open AAA repair Statin users undergoing endovascular AAA repair Non-users undergoing open AAA
repair Non-users undergoing endovascular AAA repair. (b). Cardiac event free survival of patients undergoing endovascular or
open AAA repair, divided into statin users or non-users. Statin users undergoing open AAA repair. Statin users undergoing
endovascular AAA repair. Non-users undergoing open AAA repair Non-users undergoing endovascular AAA repair.
650 O. Schouten et al.determined by the presence and extent of underlying
coronary artery disease.8 In the landmark study performed
over 20 years ago Hertzer et al. found that only 8% of
a group of 1000 patients undergoing noncardiac vascular
surgery had normal coronary angiography results.9 This high
prevalence of underlying cardiac disease has later also
been confirmed by functional tests such as dobutamine
stress echocardiography.10 Considering this high prevalence
of coronary artery disease in vascular surgery patients it is
hardly surprising that cardiac death after AAA repair
accounts for approximately 40% and 65% of all 30-day and
long-term mortality, respectively.11 It might be argued that
optimal medical therapy is warranted to sustain the initial
cardiovascular survival benefit in patients who underwent
endovascular AAA repair.
In previous studies perioperative and long-term statin
therapy have been associated with improved outcome in0
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Figure 3 Overall survival of patients undergoing endovas-
cular or open AAA repair, divided into patients not on adequate
beta-blocker therapy and statin therapy, patients on either
adequate beta-blocker therapy or statin therapy, and patients
on both adequate beta-blocker therapy and statin therapy.
Statin therapy and adequate beta-blocker therapy. Statin
therapy or adequate beta-blocker therapy No statin therapy
and no adequate beta-blocker therapy.patients undergoing AAA repair. Several recent retrospec-
tive studies have shown a beneficial effect of statins on
perioperative cardiac outcome with adjusted hazard ratio’s
ranging from 0.20 to 0.62.12 Importantly, Kertai et al. also
found the effect of statins to be independent of b-blocker
use.13 So far only one placebo-controlled, randomized trial
has investigated the influence of statin use on perioperative
cardiovascular complications. In a group of 100 patients
treatment with 20 mg of atorvastatin was associated with
a significant 3.1-fold (pZ 0.022) reduction in cardiovas-
cular complications within 6 months after vascular
surgery.14 Kertai et al. described the influence of statin use
on long-term outcome after open AAA repair in 570 patients
with a median follow-up of 4.7 years.15 It was shown that,
in this group of unselected AAA patients, statin use was
associated with a 2.5-fold reduction in the risk of all-cause
mortality (HR 0.4; 95% CI 0.3e0.5) and a 3-fold reduction
in the risk of cardiovascular mortality (HR 0.3; 95% CI
0.2e0.6). Interestingly, the present study included only
high cardiac risk patients but the reduction in the risk for
mortality and cardiovascular complications was similar to
the reported figures of Kertai et al.
Importantly statin use is advocated in the recent TASC II
document.16 Patients with symptomatic or asymptomatic
peripheral arterial disease should have their LDL lowered to
less than 2.59 mmol/l. Patients with multiple vascular beds
affected should be treated even more aggressively with
a target LDL <1.81 mmol/l. It should be noted that the
cardioprotective effect of statins might not only be by
reducing LDL levels but statins might also exert their
protective effects by so-called pleiotropic effects.
Another medical intervention that has been proven
successful in high-risk patients undergoing major vascular
surgery is beta-blocker therapy. In the DECREASE I trial
patients with preoperative stress inducible myocardial
ischemia had a mere 10-fold reduction in perioperative
cardiac events compared to patients who received placebo
treatment.17 Additionally, during a median follow-up of
22 months only 12% of patients on beta-blocker therapy
experienced a cardiac event vs 32% of the patients who
Cardiac High-Risk and EVAR 651were not on beta-blocker therapy (pZ 0.025).18 This
treatment effect was later confirmed in the DECREASE I
registry patients in which 1299 survivors of vascular surgery
were followed for a median duration of 23 months.19 In
multivariable analysis the 360 patients on beta-blockers
had a significant risk reduction for cardiac events (HR 0.3;
95% CI 0.2e0.6; P< 0.001). However, recently some trials
were published that questioned the potential benefit of
beta-blockers in vascular surgery patients. In particular the
POISE trial might have a negative impact on the willingness
to prescribe beta-blockers to patients undergoing major
vascular surgery. In the POISE trial the investigators found
an increased risk for all-cause death in patients using beta-
blockers, in particular driven by an excess in perioperative
strokes.20 There are several explanations for the findings in
POISE related to dosing, duration of therapy, beta-blocker
withdrawal and adequate titration.21 When keeping this in
mind, beta-blocker therapy still is safe and effective, in
particular in patients at high cardiac risk as in the current
study.
It should be noted that the patients in the current study
were considered to be at high cardiac risk which does not
imply that they were considered to be unfit for surgery in
general. The term cardiac high-risk in this study is based on
our observations in the DECREASE I and II trials.22 Patients
with 3 or more risk factors as in the present study had a
4-fold and 28-fold increased risk for perioperative cardiac
events as compared to patients at intermediate or low risk
respectively. In terms of overall survival, patients in the
current study had a worse outcome compared to patients in
EVAR-1 and DREAM but a much better outcome compared to
patients in EVAR-2.1,23,24 Furthermore, the current study is
not a randomized trial and as such has obvious limitations
related to the nature of the study. However, keeping these
limitations in mind, and using multivariable regression
analysis with propensity scoring, the results of this study
are in line with previous published studies. It reemphasizes
the need for optimal medical therapy in high-risk patients
scheduled for AAA repair irrespective of the choice of
treatment modality. Physicians should not be pacified by
the thought that endovascular treatment is a less invasive
treatment, therefore being less stressful for the heart and
hence requiring less aggressive medical therapy. On the
contrary, in the end patients undergoing endovascular AAA
repair could even benefit more from aggressive medical
therapy as the initial benefit of endovascular repair might
be sustained in these patients.Acknowledgement
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